Nelarabine Disease Interactions
There are 5 disease interactions with nelarabine.
Nelarabine (applies to nelarabine) neurotoxicity
Major Potential Hazard, Moderate plausibility. Applicable conditions: Neurologic Disorder, History - Radiation Therapy
Severe neurologic adverse reactions have been reported with the use of nelarabine. Neurotoxicity is the dose-limiting toxicity of nelarabine. Patients treated previously or concurrently with intrathecal chemotherapy or previously with craniospinal irradiation may be at increased risk for neurologic adverse events. Close monitoring for neurologic adverse reactions is strongly recommended, when using nelarabine and therapy should be discontinued for neurologic adverse reactions of NCI Common Toxicity Criteria Grade 2 or greater.
Nelarabine (applies to nelarabine) vaccination
Major Potential Hazard, Moderate plausibility.
Immunocompromised patients receiving nelarabine should avoid receiving live vaccines.
Nelarabine (applies to nelarabine) liver dysfunction
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
The influence of hepatic impairment on the pharmacokinetics of nelarabine has not been evaluated. Because the risk of adverse reactions to this drug may be greater in patients with severe hepatic impairment (total bilirubin greater than 3 times upper limit of normal), it is recommended to closely monitor patients with severe liver dysfunction when treated with nelarabine.
Nelarabine (applies to nelarabine) renal impairment
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction
Nelarabine has not been studied in patients with renal dysfunction. There are insufficient data to support a dose recommendation for patients with a CrCl less than 50 mL/min. Because the risk of adverse reactions to this drug may be greater in patients with moderate (CrCl 30 to 50 mL/min) or severe (CrCl less than 30 mL/min) renal impairment, these patients should be closely monitored for toxicities if treated with this drug.
Nelarabine (applies to nelarabine) tumor lysis syndrome
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Hyperuricemia Secondary to Chemotherapy
Patients receiving nelarabine should receive intravenous hydration according to standard medical practice for the management of hyperuricemia in patients at risk for tumor lysis syndrome. Consideration should be given to the use of allopurinol in patients at risk of hyperuricemia.
Switch to professional interaction data
Nelarabine drug interactions
There are 328 drug interactions with nelarabine.
More about nelarabine
- nelarabine consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- During pregnancy
- Drug class: antimetabolites
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Gleevec
Gleevec is targeted cancer therapy for specific types of leukemia (blood cancer), bone marrow ...
Sprycel
Sprycel is used to treat chronic myeloid leukemia and acute lymphoblastic leukemia. Learn about ...
Dupixent
Dupixent is used to treat eczema, eosinophilic or oral-corticosteroid-dependent asthma, chronic ...
Adriamycin
Adriamycin is used for acute lymphoblastic leukemia, acute myeloblastic leukemia, bladder cancer ...
Ponatinib
Ponatinib is used to treat chronic myeloid leukemia and Philadelphia chromosome positive acute ...
Blinatumomab
Blinatumomab (Blincyto) is an injectable immunotherapy treatment that may be used to treat B-cell ...
Mercaptopurine
Mercaptopurine is used for acute lymphoblastic leukemia, autoimmune hepatitis, crohn's disease ...
Dasatinib
Dasatinib is used to treat Philadelphia chromosome-positive chronic myelogenous leukemia (CML) ...
Imatinib
Imatinib is used to treat certain types of leukemia, bone marrow disorders, and skin cancer ...
Doxorubicin
Doxorubicin is used for acute lymphoblastic leukemia, acute myeloblastic leukemia, bladder cancer ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.